Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

Also called NCT02072330

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 353 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02072330
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02072330. Randomized; quadruple masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2013-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
Condition
Grade I or II Essential Hypertension
Intervention (Drug)
TAK-536CCB
Intervention (Drug)
TAK-536CCB + Hydrochlorothiazide
Intervention (Drug)
Hydrochlorothiazide
Intervention (Drug)
Hydrochlorothiazide
Intervention (Drug)
TAK-536CCB + Hydrochlorothiazide
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02072330
Content hash
a2fbd9ac381af24c604733baf61d6b11ac7d3fdda8afd563282cb0ceb75a5dd0